Infinity Bio Introduces Cutting-edge Antibody Profiling Platform Incorporating MIPSA Technology
Thursday, February 01, 2024
Infinity Bio, Inc. proudly introduces its innovative antibody profiling platform, driven by the state-of-the-art Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This groundbreaking platform represents a significant advancement in immune system analysis, propelling research in immunology, virology, autoimmunity, and allergy studies. It promises to provide unparalleled insights into diseases, discover novel biomarkers, and facilitate the development of groundbreaking treatments.
MIPSA technology leverages recent advancements in high-throughput DNA sequencing and synthesis to create and analyze exhaustive panels of immune targets. The immune system's ability to generate antibodies from an astonishing one quadrillion options allows it to identify and neutralize various threats. Infinity Bio's MIPSA technique scrutinizes this vast array of antibodies present in blood or other fluids, offering a comprehensive understanding of individual immune responses.
Infinity Bio's proprietary MIPSA technology achieves unparalleled breadth and resolution in mapping molecular targets of immune responses. The company's catalog of antigen panels – VirSIGHT, HuSIGHT, and AllerSIGHT – integrates full-length protein and peptide libraries, enabling the most comprehensive assay for detecting antibodies targeting human viruses, self-proteins, or allergic proteins in a single test. This positions Infinity Bio at the forefront of disease research, biomarker discovery, monoclonal antibody optimization, vaccine development, and therapeutic advancement.
Infinity Bio, emphasizes the company's commitment to surpassing the limits of previous technologies. The purpose-built laboratory, equipped with best-in-class infrastructure and processes, is designed to handle large sample and data sets, providing cutting-edge analyses and valuable insights into disease etiology. Infinity Bio's services aim to support academic and pharmaceutical researchers, including large cohort studies, enhancing clinical trial outcomes and therapy selection.
The applications of Infinity Bio's antibody profiling services are diverse:
- Cohort Studies: Identifying disease mechanisms, triggers, and modifiers.
- Clinical Trials: Enhancing patient phenotypic characterization based on immune responses.
- Vaccine Development: Linking antibody responses to vaccine efficacy and identifying unforeseen liabilities.
- Immuno-Oncology Therapeutics: Utilizing autoantibody analysis to discover novel cancer targets and identify potential adverse events early.
- Biomarker Discovery: Uncovering biomarkers for infectious and autoimmune diseases through unbiased patient antibody profiling.
- Monoclonal Antibody Characterization: Precisely defining the binding profiles of clinical or reagent-grade antibodies.
Infinity Bio's Science-as-a-Service model offers detailed, comprehensive, and reproducible antibody response analyses. The company's scalability and unique custom library design flexibility position it as a valuable partner in biomedical research.
Infinity Bio, highlights the company's mission to elucidate each individual's portfolio of antibodies, providing new perspectives on how the immune system perceives the world.
Infinity Bio, emphasizes the potential of robust and comprehensive antibody profiling to unlock insights into various human diseases.
Infinity Bio is not just a service provider but a partner in healthcare innovation, recognizing the central role of inflammation and immunity in human disease and its treatment.
Infinity Bio was launched with investments from PTX Capital and Blackbird BioVentures.
Source: businesswire.com
